Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Katia Thokagevistk
Observed names:
K Thokagevistk,
K. Thokagevistk,
Katia Thokagevistk-Desroziers,
Thokagevistk, Katia
Institution:
Roche (France)
Observed institutions:
Roche (France),
Creativ-Ceutical (France)
OpenAlex ID:
A5063733763
Health economic evaluation of gene replacement therapies: methodological issues and recommendations
2020
·
Samuel Aballéa
, Katia Thokagevistk
, et al.
·
Journal of Market Access & Health Policy
·
30
PDF
Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
2014
·
Samuel Aballéa
, Khaled Maman
, et al.
·
Clinical Drug Investigation
·
26
PDF
Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
2020
·
Mondher Toumi
, Aurélie Millier
, et al.
·
Frontiers in Medicine
·
16
PDF
Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance
2024
·
Katia Thokagevistk
, Céline Coppo
, et al.
·
Journal of Market Access & Health Policy
·
15
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
2023
·
Hervé Ghesquières
, Fanny Cherblanc
, et al.
·
Blood Advances
·
13
PDF
Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States
2018
·
Mairead Kearney
, Katia Thokagevistk
, et al.
·
Journal of Medical Economics
·
9
PDF
Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations
2016
·
Katia Thokagevistk
, Aurélie Millier
, et al.
·
Journal of Market Access & Health Policy
·
6
Addressing challenges with Matching-Adjusted Indirect Comparisons to demonstrate the comparative effectiveness of entrectinib in metastatic ROS-1 positive Non-Small Cell Lung Cancer
2025
·
Cyril Esnault
, Louise Baschet
, et al.
·
BMC Medical Research Methodology
·
2
P1186: a Large French Real World Multicentric Prospective Cohort of Patients With Lymphoma (realysa Study): Description of the Diffuse Large B Cell Lymphoma Patients in Real World in France
2022
·
H. Ghesquieres
, F. Cherblanc
, et al.
·
HemaSphere
·
2
From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses
2019
·
Katia Thokagevistk
, Clément François
, et al.
·
Journal of Market Access & Health Policy
·
2
PDF
Impact of health insurance status on health care resource utilization among diabetic patients in the United States
2014
·
F.M. Dabbous
, J. Dorey
, et al.
·
Value in Health
·
2
RWD45 Real-World Data to Support Surrogate Endpoint Evaluation for Health Technology Assessment
2022
·
J Dupin
, K Thokagevistk
, et al.
·
Value in Health
·
1
PDF
Pns12 Factors to Be Considered to Ensure Acceptability of Historically Controlled Studies by Hta Bodies
2019
·
C. Rémuzat
, K. Thokagevistk
, et al.
·
Value in Health
·
1
Pcn127 - Direct Healthcare Costs by Treatment Among Patients With Merkel Cell Carcinoma (mcc) in the United States
2018
·
M. Kearney
, K. Thokagevistk
, et al.
·
Value in Health
·
1
PDF
Healthcare resource use and expenditures among patients with Merkel cell carcinoma by level of comorbidity.
2018
·
Mairead Kearney
, Katia Thokagevistk
, et al.
·
Journal of Clinical Oncology
·
1
Global Burden of Seasonal Influenza Disease: A Structured Literature Review
2018
·
K Thokagevistk
, S Aballéa
, et al.
·
Value in Health
·
1
PDF
Evolution Of Tiotropium Efficacy Vs. Placebo Over Time For The Maintenance Therapy Of Chronic Obstructive Pulmonary Disease: From Investigational Product To Active Reference
2015
·
K Thokagevistk
, A Khemiri
, et al.
·
Value in Health
·
1
HSD105 Subcutaneous vs. Intravenous Administration in Oncology: A Literature Review of Impacts on Patients, Providers, and Hospitals
2025
·
Katia Thokagevistk
, Sarah Mir
, et al.
·
Value in Health
1827P Testing patterns and outcomes in unresected stage III non-small cell lung cancer (NSCLC): Insights from a nationwide French real-world cohort
2025
·
O. Molinier
, D. Debieuvre
, et al.
·
Annals of Oncology
1811eP Testing patterns and outcomes in resected stage I-III non-small cell lung cancer (NSCLC): Insights from a nationwide French real-world cohort
2025
·
D. Debieuvre
, L. Goncalves
, et al.
·
Annals of Oncology
FALCONS, une étude rétrospective non interventionnelle chez des patients atteints de CBNPC réséqué utilisant la base de données EPITHOR : premières analyses
2025
·
M. Wislez
, M. Alifano
, et al.
·
Revue des Maladies Respiratoires Actualités
MSR156 Quantifying Bias in Matching Adjusted Indirect Comparisons (MAIC): A Case Study With Entrectinib in Metastatic ROS-1 Positive Non-Small Cell Lung Cancer (NSCLC)
2024
·
C Esnault
, L Baschet
, et al.
·
Value in Health
PDF
1218P FALCONS, a non-interventional retrospective study in resected NSCLC patients using the EPITHOR database, first analysis
2024
·
M. Wislez
, M. Alifano
, et al.
·
Annals of Oncology
PDF
Impact de la voie d’administration sous-cutanée pour les professionnels de santé, les patients et les organismes payeurs : résultats d’une revue de la littérature
2024
·
A. Groenez
, C. Esnault
, et al.
·
Revue des Maladies Respiratoires Actualités
EE676 Cost Considerations: Exploring the Economic Implications of Choosing SC or IV Administration
2023
·
A. Gherardi
, S. Gally
, et al.
·
Value in Health
PDF
Show more works
View as search
Works count:
42
Citation count:
129
H-index:
6
I10-index:
5
Year
Topic
Type
